KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Operating Leases (2019 - 2025)

Historic Operating Leases for Charles River Laboratories International (CRL) over the last 7 years, with Q3 2025 value amounting to $443.2 million.

  • Charles River Laboratories International's Operating Leases rose 239.1% to $443.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $443.2 million, marking a year-over-year increase of 239.1%. This contributed to the annual value of $483.8 million for FY2024, which is 203.46% up from last year.
  • Per Charles River Laboratories International's latest filing, its Operating Leases stood at $443.2 million for Q3 2025, which was up 239.1% from $453.7 million recorded in Q2 2025.
  • Over the past 5 years, Charles River Laboratories International's Operating Leases peaked at $483.8 million during Q4 2024, and registered a low of $198.9 million during Q1 2021.
  • For the 5-year period, Charles River Laboratories International's Operating Leases averaged around $383.5 million, with its median value being $418.1 million (2024).
  • In the last 5 years, Charles River Laboratories International's Operating Leases surged by 6083.19% in 2021 and then dropped by 3.54% in 2024.
  • Over the past 5 years, Charles River Laboratories International's Operating Leases (Quarter) stood at $286.2 million in 2021, then soared by 52.41% to $436.3 million in 2022, then grew by 8.68% to $474.1 million in 2023, then increased by 2.03% to $483.8 million in 2024, then decreased by 8.39% to $443.2 million in 2025.
  • Its Operating Leases was $443.2 million in Q3 2025, compared to $453.7 million in Q2 2025 and $475.1 million in Q1 2025.